2-氧代-1,2,3,4-四氢喹啉-4-羧酸 | 14179-84-1

• 物质功能分类: 医药中间体 - 杂环化合物 - 喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 2-氧代-1,2,3,4-四氢喹啉-4-羧酸
• 中文别名: 2-氧代-3,4-二氢-1H-喹啉-4-羧酸；1,2,3,4-四氢-2-氧代喹啉-4-羧酸
• 英文名称: 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid
• 英文别名: 2-oxo-1,2,3,4-tetrahydro-quinoline-4-carboxylic acid；2-Oxo-1,2,3,4-tetrahydro-chinolin-4-carbonsaeure；2-Oxo-1.2.3.4-tetrahydro-chinolin-carbonsaeure-(4)；2-oxo-3,4-dihydro-1H-quinoline-4-carboxylic acid
• CAS: 14179-84-1
• 化学式: C₁₀H₉NO₃
• mdl: MFCD02046626
• 分子量: 191.186
• InChiKey: UFTLCDHPTBFVHE-UHFFFAOYSA-N

物化性质

• 熔点：
  220 °C
• 沸点：
  444.4±45.0 °C(Predicted)
• 密度：
  1.355±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933790090

反应信息

• 作为反应物：
  描述：

  2-氧代-1,2,3,4-四氢喹啉-4-羧酸 在 palladium on activated charcoal 氢气 、 potassium carbonate 、 三乙胺 、 sodium iodide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 4-[4-(3-Oxo-3-phenyl-propyl)-piperazine-1-carbonyl]-3,4-dihydro-1H-quinolin-2-one
  参考文献：
  名称：

  Studies on positive inotropic agents. II. Synthesis of (4-substituted 1-piperazinylcarbonyl)-2-(1H)-quinolinone derivatives.

  摘要：

  合成了多种(1-哌嗪基羰基)-2(1H)-喹啉酮衍生物，并对其在犬心脏上的正性肌力活性进行了检查。其中，3, 4-二氢-6-[4-(3-氧代-3-苯基丙基)-1-哌嗪基羰基]-2(1H)-喹啉酮 (XXIj) 和 3, 4-二氢-6-[4-(氧代-4-苯基丁基)-1-哌嗪基羰基]-2(1H)-喹啉酮 (XXIl) 被发现具有强效活性。

  DOI：

  10.1248/cpb.34.682
• 作为产物：
  描述：

  (2-nitro-phenyl)-succinic acid 在 氨 、 iron(II) sulfate 作用下， 生成 2-氧代-1,2,3,4-四氢喹啉-4-羧酸
  参考文献：
  名称：

  Fichter; Walter, Chemische Berichte, 1909, vol. 42, p. 4312

  摘要：

  DOI：

文献信息

• Pharmaceutical composition and method for modulating the immune reaction
  申请人：Cerbios-Pharma SA

  公开号：US05849756A1

  公开（公告）日：1998-12-15

  Pharmaceutical compositions for the modulation of the immune reaction of warm blooded animals that are derivatives of the 2-oxindole-3-acetic acid or the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, and whereby the derivatives can optionally be in an equilibrium with each other. The derivatives included in the pharmaceutical compositions comprise those compounds which are already described in the literature and also new compounds. Furthermore, new derivatives of the the 2-oxindole-3-acetic acid and the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid are described, particularly also the the pure antipodes of the mixture of enantiomeres of the 2-oxo-1,2,3,4-tetrahydroquinoline-4-carboxylic acid.

  描述了用于调节温血动物免疫反应的药物组合物，这些组合物是2-氧吲哚-3-乙酸或2-氧-1,2,3,4-四氢喹啉-4-羧酸的衍生物，并且这些衍生物可以选择地相互处于平衡状态。药物组合物中包括的衍生物包括那些已经在文献中描述的化合物以及新的化合物。此外，还描述了2-氧吲哚-3-乙酸和2-氧-1,2,3,4-四氢喹啉-4-羧酸的新衍生物，特别是2-氧-1,2,3,4-四氢喹啉-4-羧酸的对映体混合物的纯对映体。
• Compounds, pharmaceutical compositions and methods of use therefor
  申请人：Ghosh Shomir

  公开号：US20050143372A1

  公开（公告）日：2005-06-30

  The invention relates to compounds having the formula (I). Preferred compounds are antagonists of C—C chemokine receptor 8. The invention also relates to a method for treating a subjected having an inflammatory disorder or viral disorder comprising administering to a subject in need thereof an effective amount of a compound of the invention.

  该发明涉及具有公式（I）的化合物。首选化合物是C-C趋化因子受体8的拮抗剂。该发明还涉及一种治疗患有炎症性疾病或病毒性疾病的受试者的方法，该方法包括向需要的受试者施用该发明的化合物的有效量。
• Novel amide derivatives and medicinal use thereof ugs
  申请人：——

  公开号：US20040138223A1

  公开（公告）日：2004-07-15

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action 1 wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防因C5a引起的炎症引起的疾病或综合症的药物，如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，哮喘等过敏性疾病，动脉粥样硬化，心脏梗死，脑梗死，牛皮癣，老年痴呆症和严重器官损伤（如肺炎，肾炎，肝炎，胰腺炎等）由于缺血再灌注，创伤，烧伤，手术入侵等引起的白细胞激活。此外，它们对通过C5a受体侵入的细菌和病毒引起的传染病也有用作治疗或预防剂。
• PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS
  申请人：Rogel Olivier

  公开号：US20090247577A1

  公开（公告）日：2009-10-01

  Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (disorder) that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on the activity of beta-secretase and/or the generation of beta-amyloid and the subsequent aggregation into oligomers and fibrils; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound. The substituted pyrrolidine compounds are especially of the formula I, wherein the substituents are as defined in the specification.

  小说3-单取代、3,4-双取代和3,4,4-三取代吡咯烷化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病（紊乱）；该类化合物的使用用于制备用于治疗依赖于β-分泌酶活性和/或β-淀粉样蛋白生成及其后续寡聚体和纤维聚集的疾病的药物配方；包括所述取代的吡咯烷化合物的药物配方和/或包括给予该取代的吡咯烷化合物的治疗方法。所述取代的吡咯烷化合物特别是公式I的，其中取代基如规范中所定义。
• Novel amide derivatives and medicinal use thereof
  申请人：NAKAMURA Mitsubaru

  公开号：US20100041656A1

  公开（公告）日：2010-02-18

  The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action wherein each symbol is as defined in the specification. The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.

  本发明涉及一种式（1）的酰胺衍生物，具有C5a受体拮抗作用，其中每个符号如规范中所定义。上述酰胺衍生物及其光学活性形式和药学上可接受的盐被认为是治疗或预防由C5a引起的炎症所致疾病或综合症的药物，例如自身免疫性疾病，如风湿病，系统性红斑狼疮等，败血症，成人呼吸窘迫综合症，慢性阻塞性肺疾病，过敏性疾病，如哮喘等，动脉硬化，心脏梗塞，脑梗塞，牛皮癣，阿尔茨海默病和严重器官损伤（例如，肺炎，肾炎，肝炎，胰腺炎等），由缺血再灌注，创伤，烧伤，手术侵袭等引起的白细胞激活所致。此外，它们还可用作通过C5a受体侵入的细菌和病毒引起的传染病的治疗或预防剂。

表征谱图